ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro

Abstract

The thromboxane A2 synthase (TXS) inhibitory activity and the thromboxane A2 (TP)‐receptor blocking action of ZD1542 (4(Z)‐6‐[2S,4S,5R)‐2‐[1‐methyl‐1‐(2‐nitro‐4‐tolyloxy)ethyl]‐4‐(3‐pyridyl)‐1,3‐dioxan‐5‐yl]hex‐4‐enoic acid) has been evaluated in vitro on platelets and whole blood from a range of species including man. Antagonist activity has also been investigated in vascular and pulmonary smooth muscle preparations in vitro. ZD1542 caused concentration‐dependent inhibition of human platelet microsomal thromboxane B2 (TXB2) production in vitro (IC50 = 0.016 μm); this inhibition was associated with an increase in prostaglandin E2 (PGE2) and PGF2α formation. ZD1542 also inhibited collagen‐stimulated TXS in human, rat and dog whole blood giving IC50 values of 0.018, 0.009 and 0.049 μm respectively. The drug did not modify platelet cyclo‐oxygenase activity as inhibition of TXB2 formation was associated with a concomitant increase in the levels of PGD2, PGE2 and PGF2α. ZD1542 had little if any effect against cultured human umbilical vein endothelial cell (HUVEC) cyclo‐oxygenase (IC50 > 100 μm) and prostacyclin (PGI2) synthase (IC50 = 18.0 ± 8.6 μm). ZD1542 caused concentration‐dependent inhibition of U46619‐induced aggregation responses of human, rat and dog platelets yielding apparent pA2 values of 8.3, 8.5 and 9.1 respectively. The drug was selective as, at concentrations up to 100 μm, it did not modify 5‐hydroxytryptamine (5‐HT) or the primary phases of adenosine diphosphate (ADP) and adrenaline‐induced aggregation. Furthermore, ZD1542 (100 μm) modified only weakly the platelet inhibitory effects of PGD2, PGE1 and PGI2. ZD1542 also caused concentration‐dependent inhibition of U46619‐mediated contractions of rat thoracic aorta, guinea‐pig trachea and lung parenchyma preparations giving apparent pA2 values of 8.6, 8.3 and 8.5 respectively. At concentrations approaching three orders of magnitude greater than those required to block U46619‐mediated contractions, the drug did not affect the actions of non‐prostanoid agonists or exhibit agonist activity in any of the smooth muscle preparations employed; neither did it interact at EP‐ or FP‐receptors. In conclusion, the present study demonstrates that ZD1542 is a drug that exhibits both potent, selective TXS inhibition and TXA2 receptor antagonism. 1993 British Pharmacological Society